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Background 
•  End-stage kidney disease (ESKD) patients have substantially increased mortality compared to the general population. 
•  Conventional haemodialysis (HD) of 3 sessions per week of up to 5 hours per session became the mainstay of treatment in the 1970s when US government legislation 
combined with observational data that thrice weekly dialysis of increasingly shorter durations was at least adequate allowed increasing access to HD.1 
•  Despite improvements in survival in both the general and ESKD populations, mortality rates remain high among dialysis patients in Australia compared to the general 
population.2 
•  Intensive HD of more frequent and or longer duration treatment has been proposed to improve survival in this population. However, it is not clear whether the improved survival 
observed in studies is attributed to increased frequency, increased duration, or both. 
Method 
•  A retrospective cohort study of HD patients using data from the Australia and 
New Zealand Dialysis and Transplant (ANZDATA) Registry. 
•  The cohort included all Australian patients aged ≥18 years who initiated HD of 
≥3 sessions/week in Australia from 1 January 2001 to 31 December  2015. 
•  Indigenous patients, patients receiving <2 sessions/week or patients who 
received <90 days of HD were excluded.  
•  Initial dialysis prescription was categorised as 3 sessions/week versus >3 
sessions/week, and session durations ≤5 hours/session versus >5 hours/
session. 
•  Patients were censored at death, transplant, change of dialysis modality or 
recovery of native kidney function, or 31 December 2015, whichever came first.  
•  The main outcome was patient mortality.  
•  Survival analysis was performed using Cox regression analysis, with 
multivariable analysis controlling for available covariates. 
•  The final regression model included an interaction term between session 
frequency and session length. 
Results 
•  In total, 16,944 patients were included in survival analyses with a combined 
follow up time of 54478.2 person-years.  
•  Cohort characteristics and outcomes are summarised in Table 1 and Table 2. 
•  Adjusted Survival Curves shown in Figure 1 and Figure 2. 
Conclusion 
•  Results indicate that initial longer session durations >5 hours, but not more frequent HD, are associated with improved survival on dialysis in non-Indigenous Australian adult 
ESKD patients initiating HD. 
•  This suggests that it is the increased duration of intensive dialysis rather than the increased frequency that has the greatest effect on survival in these patients.  
•  Further analyses are required to investigate the potential causal mechanisms, as well as the optimal HD prescription that achieves greatest patient tolerability and outcomes for 
dialysis patients, not only for survival but quality of life. 
Figure 2: Adjusted survival curve showing advantage of longer session 
length (>5 hours/ session) compared to conventional duration of up to 5 
hours/session. 
Figure 1: Adjusted survival curve showing comparable survival of frequent 
(>3 sessions/week) and conventional 3 sessions/week HD. 
AIM - This analysis of Australian registry data aimed to assess the independent effects of session 
frequency and session duration on all-cause mortality in incident ESKD patients receiving HD. 
Table 2: Summary of Main Outcomes 
Table 1: Summary of Cohort Characteristics 
 Total 3 sessions/week 
>3 sessions/




session  P 
Number (%) 16944 (100) 16187 (95.5) 757 (4.5)  16426 (96.9) 518 (3.1)  
Mortality, deaths/100 
person-years 
15.58 15.89 8.77 <0.001 15.95 5.08 <0.001 
Median Survival, years 
(CI) 
4.62 (4.50 - 
4.72) 4.53 (4.42 - 4.65) 7.00 (6.47 - 8.73) 4.5 (1.40 - 4.63) 
10.5 (7.82 - 
indef.) 
Adjusted Hazard of 










  n = 16944 n = 16187 n = 757   n = 16426 n = 518   
Male, n (Pct.) 10989 (64.9) 10426 (64.4) 563 (74.4) <0.001 10564 (64.3) 425 (82.0) <0.001 
Age, mean (SD) 62.73 (14.88) 63.16 (14.75) 53.53 (14.71) <0.001 63.10 (14.79) 50.83 (12.83) <0.001 
BMI kg/m2, mean (SD) 28.50 (7.04) 28.43 (7.02) 30.04 (7.39) <0.001 28.39 (6.97) 31.94 (8.26) <0.001 
Smoking history (current/
former), n (Pct.) 9357 (55.2) 8970 (55.4) 387 (51.1) 0.022 9083 (55.3) 274 (52.9) 0.3 
Primary disease, n (Pct.) 
Glomerulonephropathies 3827 (22.6) 3601 (22.2) 226 (29.9) 3660 (22.3) 167 (32.2) 
Analgesic 382 (2.3) 373 (2.3) 9 (1.2) 381 (2.3) 1 (0.2) 
HTN or Renovascular 2674 (15.8) 2581 (15.9) 93 (12.3) 2620 (16.0) 54 (10.4) 
Polycystic 1187 (7.0) 1065 (6.6) 122 (16.1) 1106 (6.7) 81 (15.6) 
Diabetes 5258 (31.0) 5092 (31.5) 166 (21.9) 5126 (31.2) 132 (25.5) 
Reflux 419 (2.5) 382 (2.4) 37 (4.9) 399 (2.4) 20 (3.9) 
Uncertain 995 (5.9) 962 (5.9) 33 (4.4) 979 (6.0) 16 (3.1) 
Other 2202 (13.0) 2131 (13.2) 71 (9.4) <0.001 2155 (13.1) 47 (9.1) <0.001 
Comorbidities, n (Pct.) 
Chronic Lung Disease 2891 (17.1) 2808 (17.3) 83 (11.0) <0.001 2836 (17.3) 55 (10.6) <0.001 
Ischemic Heart Disease 7299 (43.1) 7088 (43.8) 211 (27.9) <0.001 7171 (43.7) 128 (24.7) <0.001 
Peripheral Vascular 
Disease 4556 (26.9) 4424 (27.3) 132 (17.4) <0.001 4477 (27.3) 79 (15.3) <0.001 
Cerebral Vascular 
Disease 2652 (15.7) 2597 (16.0) 55 (7.3) <0.001 2617 (15.9) 35 (6.8) <0.001 
Diabetes 7298 (43.1) 7057 (43.6) 241 (31.8) <0.001 7114 (43.3) 184 (35.5) <0.001 
Ever Diagnosed Cancer 4747 (28.0) 4570 (28.2) 177 (23.4) 0.004 4636 (28.2) 111 (21.4) 0.001 
Hours/session, median 
(IQR) 4 (4-5) 4 (4-4.5) 5 (4-6) 4 (4-4.5) 6 (6-8) 
Sessions/week, median 
(IQR) 3 (3-3) 3 (3-3) 4 (3.5-4) 3 (3-3) 3 (3-3.5) 
Location, n (Pct) 
In-centre, n (Pct.) 16851 (99.5) 16121 (99.6) 730 (96.4) 16344 (99.5) 507 (97.9) 
Home, n (Pct.) 93 (0.5) 66 (0.4) 27 (3.6) <0.001 82 (0.5) 11 (2.1) <0.001 
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